CONTEXT: Cancer genetics is fundamental for preventive medicine, in particular in pheochromocytoma-associated syndromes. Variants in two susceptibility genes, SDHC and RET, were found in a kindred with head and neck paraganglioma. This observation of coincident DNA variants, both reported as pathogenic, in two known susceptibility genes prompted the question of their pathogenic relevance. OBJECTIVE: Our objective was to elucidate the pathogenic role of the detected variants and study the prevalence of such variants. PATIENTS: Patients were registrants from the European-American Pheochromocytoma-Paraganglioma and German von Hippel-Lindau Disease Registries. DESIGN: Analysis of germline mutation screening results for all pheochromocytoma-paraganglioma susceptibility genes, including RET [multiple endocrine neoplasia type 2 (MEN 2)] and VHL [von Hippel-Lindau disease (VHL)]. Cases in which more than one DNA variant was found were clinically reevaluated, and cosegregation of the disease with the variant was analyzed within the registrants' families. A total of 1000 controls were screened for the presence of detected variants, and in silico analyses were performed. RESULTS: Three variants were identified, RET p.Tyr791Phe and p.Ser649Leu and VHL p.Pro81Ser. The frequencies of RET p.Ser649Leu (0.07%) and p.Tyr791Phe (0.9%) compared with controls excluded the two variants' role in the etiology of MEN 2 and VHL. None of the carriers of the RET variants who underwent prophylactic thyroidectomy showed medullary thyroid carcinoma. Clinical reinvestigation of 18 variant carriers excluded MEN 2. VHL variant p.Pro81Ser, also previously described as a mutation, did not segregate with the VHL in one family. In silico analyses for these variants predicted unmodified protein function. CONCLUSIONS: RET p.Tyr791Phe and p.Ser649Leu and VHL p.Pro81Ser are definitely not pathogenic mutations for VHL and MEN 2. Misinterpretation results in irreversible clinical consequences.
CONTEXT: Cancer genetics is fundamental for preventive medicine, in particular in pheochromocytoma-associated syndromes. Variants in two susceptibility genes, SDHC and RET, were found in a kindred with head and neck paraganglioma. This observation of coincident DNA variants, both reported as pathogenic, in two known susceptibility genes prompted the question of their pathogenic relevance. OBJECTIVE: Our objective was to elucidate the pathogenic role of the detected variants and study the prevalence of such variants. PATIENTS: Patients were registrants from the European-American Pheochromocytoma-Paraganglioma and German von Hippel-Lindau Disease Registries. DESIGN: Analysis of germline mutation screening results for all pheochromocytoma-paraganglioma susceptibility genes, including RET [multiple endocrine neoplasia type 2 (MEN 2)] and VHL [von Hippel-Lindau disease (VHL)]. Cases in which more than one DNA variant was found were clinically reevaluated, and cosegregation of the disease with the variant was analyzed within the registrants' families. A total of 1000 controls were screened for the presence of detected variants, and in silico analyses were performed. RESULTS: Three variants were identified, RETp.Tyr791Phe and p.Ser649Leu and VHLp.Pro81Ser. The frequencies of RETp.Ser649Leu (0.07%) and p.Tyr791Phe (0.9%) compared with controls excluded the two variants' role in the etiology of MEN 2 and VHL. None of the carriers of the RET variants who underwent prophylactic thyroidectomy showed medullary thyroid carcinoma. Clinical reinvestigation of 18 variant carriers excluded MEN 2. VHL variant p.Pro81Ser, also previously described as a mutation, did not segregate with the VHL in one family. In silico analyses for these variants predicted unmodified protein function. CONCLUSIONS:RETp.Tyr791Phe and p.Ser649Leu and VHLp.Pro81Ser are definitely not pathogenic mutations for VHL and MEN 2. Misinterpretation results in irreversible clinical consequences.
Authors: Andreas Machens; Patricia Niccoli-Sire; Josef Hoegel; Karin Frank-Raue; Theo J van Vroonhoven; Hans-Dietrich Roeher; Robert A Wahl; Peter Lamesch; Friedhelm Raue; Bernard Conte-Devolx; Henning Dralle Journal: N Engl J Med Date: 2003-10-16 Impact factor: 91.245
Authors: K Frank-Raue; C Heimbach; S Rondot; K-H Usadel; W Meng; C Varma; R Fuchs-Hammoser; W Höppner; E Schulze; F Raue Journal: Dtsch Med Wochenschr Date: 2003-09-26 Impact factor: 0.628
Authors: Oliver Gimm; Barbara E Niederle; Theresa Weber; Maximilian Bockhorn; Jörg Ukkat; Michael Brauckhoff; Phuong Nguyen Thanh; Andreja Frilling; Ernst Klar; Bruno Niederle; Henning Dralle Journal: Surgery Date: 2002-12 Impact factor: 3.982
Authors: Thereasa A Rich; Lei Feng; Naifa Busaidy; Gilbert J Cote; Robert F Gagel; Mimi Hu; Camilo Jimenez; Jeffrey E Lee; Nancy Perrier; Steven I Sherman; Steven G Waguespack; Anita Ying; Elizabeth Grubbs Journal: Thyroid Date: 2014-06-06 Impact factor: 6.568
Authors: Kara N Maxwell; Steven N Hart; Joseph Vijai; Kasmintan A Schrader; Thomas P Slavin; Tinu Thomas; Bradley Wubbenhorst; Vignesh Ravichandran; Raymond M Moore; Chunling Hu; Lucia Guidugli; Brandon Wenz; Susan M Domchek; Mark E Robson; Csilla Szabo; Susan L Neuhausen; Jeffrey N Weitzel; Kenneth Offit; Fergus J Couch; Katherine L Nathanson Journal: Am J Hum Genet Date: 2016-05-05 Impact factor: 11.025
Authors: Diala El-Maouche; James Welch; Sunita K Agarwal; Lee S Weinstein; William F Simonds; Stephen J Marx Journal: Int J Endocr Oncol Date: 2016-04-08
Authors: Anna V Kudryavtseva; Elena N Lukyanova; Dmitry V Kalinin; Andrew R Zaretsky; Anatoly V Pokrovsky; Alexander L Golovyuk; Maria S Fedorova; Elena A Pudova; Sergey L Kharitonov; Vladislav S Pavlov; Anastasiya A Kobelyatskaya; Nataliya V Melnikova; Alexey A Dmitriev; Andrey P Polyakov; Boris Y Alekseev; Marina V Kiseleva; Andrey D Kaprin; George S Krasnov; Anastasiya V Snezhkina Journal: BMC Med Genomics Date: 2019-03-13 Impact factor: 3.063
Authors: F O F Valente; M R Dias da Silva; C P Camacho; I S Kunii; A U Bastos; C C N da Fonseca; H P C Simião; R Tamanaha; R M B Maciel; J M Cerutti Journal: J Endocrinol Invest Date: 2013-05-30 Impact factor: 4.256